Neurelis Announces Rapid and Broad Payer Coverage of the Company's Flagship Product, VALTOCO(R) (Diazepam Nasal Spray)

More than 176 million lives in the U.S. now covered by payers/managed care/insurance plans within months of FDA approval of VALTOCO, the first and only nasal spray treatment of seizure clusters in patients 6 years of age and older Neurelis' patient assi... Biopharmaceuticals, Reimbursement Neurelis, VALTOCO, diazepam, epilepsy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news